{"a":[{"_":"FDA files reveal lingering concerns, contrasting views behind Replimune melanoma nod","$":{"href":"/pharma/fda-docs-reveal-lingering-concerns-intervention-behind-replimunes-long-sought-melanoma-nod","hreflang":"en"}}]}
RegulatoryapprovedTudriqevPositive
AI Analysis
Summary
The FDA approved Replimune's Tudriqev for melanoma via accelerated approval last month, with leadership at the FDA's Office of Clinical Evaluation and Oncology Center of Excellence overruling review staff concerns to grant the nod.
Outcome Details
Accelerated FDA approval for Tudriqev in melanoma. FDA Office of Clinical Evaluation and Oncology Center of Excellence leadership overruled review staffers' concerns to grant approval.
Importance:8/10
Sentiment:
0.80
FDA approvalaccelerated approvaloncologymelanomaimmunotherapy
Read the original article
Published by FiercePharma on September 3, 2026 10:50 AM